USP's revisions to sterile compounding standards and FDA guidance; impacts on mixing of allergen extracts

For more than 100 hundred years, beginning with its introduction by Noon in 1911 for the treatment of timothy grass pollen allergy, patient-specific allergen immunotherapy has been established as an effective treatment for allergic rhinoconjunctivitis, allergic asthma, and stinging insect allergy.1 During those years, practicing allergists have mixed allergen extracts for immunotherapy in their offices and clinics with no reports of risks of untoward infections as the result of allergen immunotherapy.

http://ift.tt/2kKwxKZ